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Methods: The QDRS was tested in 267 patient-caregiver dyads compared with Clinical Dementia
Ratings (CDR), neuropsychological testing, and gold standard measures of function, mood, and
behavior. Psychometric properties including, item variability, floor and ceiling effects, concurrent
and construct validity, and internal consistency were determined. The QDRS was used to derive an
independent CDR and sum-of-boxes (SB). Interscale reliability between QDRS and CDR was tested
using intraclass correlation coefficients (ICC). Area under the receiver operator characteristic curves
(AUC) tested discrimination properties of QDRS across CDR stages.
Results: QDRS scores increased with higher CDR staging and poorer neuropsychological perfor-
mance (Ps , .001). The QDRS demonstrated low floor and ceiling effects; excellent known-
groups validity across CDR stages (Ps , .001); construct validity against cognitive, behavioral,
and functional measures (Ps 0.004 to ,0.001); and reliability (Cronbach a: 0.86–0.93). The
QDRS demonstrated differential scores across different dementia etiologies. The AUC for the
QDRS was 0.911 (95% confidence interval or CI 0.86–0.96) and for the CDR-SB was 0.996 (95%
CI 0.99–1.0) demonstrating comparable ability to discriminate normal controls from dementia.
The QDRS-generated CDR demonstrated excellent correspondence with the CDR (ICC 5 0.90)
and SB (ICC 5 0.92).
Discussion: The QDRS validly and reliably differentiates individuals with and without dementia and
accurately stages dementia without extensive training or clinician input, and is highly correlated with
our gold standard measures. The QDRS provides a rapid method to determine study eligibility, stage
patients in clinical practice, and improve case ascertainment in population studies.
 2015 The Author. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Dementia; Neurocognitive disorders; Clinical dementia rating; Staging; Clinical trials1. Background
Detection of mild cognitive impairment (MCI) [1,2] and
mild Alzheimer’s disease (AD) [3] in community samples of
older adults may be limited in part due to the lack of brief
tests that capture and characterize the earliest signs of
impairment and monitor response to therapies and interven-thor. Dr. Galvin is now located at Charles E. Schmidt
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commons.org/licenses/by-nc-nd/4.0/).tions [4,5]. This may affect eligibility determination for care
and services, impede case ascertainment in epidemiologic
studies, and inhibit the ability to identify eligible
individuals for clinical trial recruitment. Informant-based as-
sessments of intraindividual change such as the AD8 [4,6]
may be more sensitive to identify individuals with mild
impairments and better detect functional interference than
brief performance-based measures that rely on interindi-
vidual norms [7,8]. However, all brief screening methods,
whether informant-based (i.e., the AD8 [4,9]) or
performance-based (i.e., the Mini-Cog [10]), have limitedimer’s Association. This is an open access article under the CC BY-NC-ND
J.E. Galvin / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 249-259250ability to stage individuals. Gold standard evaluations (i.e.,
Clinical Dementia Rating or CDR [11]) used in many clin-
ical, translational, and health services research projects
require a trained clinician to administer, interpret, and score;
and an extended period of time with the patient and infor-
mant. Although feasible in the setting of a clinical trial,
the CDR is more difficult to apply in screening procedures
for inclusion/exclusion criteria or for case ascertainment in
community-based research, and is impractical in most clin-
ical practices. We developed the Quick Dementia Rating
System (QDRS)—a rapid dementia staging tool to meet
these needs.
The QDRS (Table 1) is a 10-item questionnaire
completed by an informant without the need for a trained
clinician or rater, and takes 3 to 5 minutes to complete.
Scores range from 0 to 30 with higher scores representing
greater cognitive impairment. Ten domains, derived from
an empiric review of the literature and the clinical experi-
ence of the author caring for patients at memory disorder
clinics, cover (1) memory and recall, (2) orientation, (3)
decision-making and problem-solving abilities, (4) activities
outside the home, (5) function at home and hobbies, (6) toi-
leting and personal hygiene, (7) behavior and personality
changes, (8) language and communication abilities, (9)
mood, and (10) attention and concentration. These domains
capture prominent symptoms of MCI, AD, and non-
Alzheimer neurocognitive disorders including Lewy body
dementia, frontotemporal degeneration, vascular dementia,
chronic traumatic encephalopathy, and depression. Each
domain has five possible answers increasing in severity of
symptoms. A particular advantage of the QDRS is the rapid
and accurate generation a valid (CDR) and its sum-of-boxes
(SB) [11]. Here we present the psychometric evaluation of
the QDRS.2. Methods
2.1. Formative development of the QDRS
The QDRS (Table 1) was first developed in a sample of 50
patients-caregiver dyads coming to evaluation at the Pearl I
Barlow Center for Memory Evaluation and Treatment, a de-
mentia specialty practice. The QDRSwas collected indepen-
dent of the clinical evaluation conducted by the author and
compared with the CDR and CDR-SB. Questions were
checked for the ease of understanding by the caregivers
and revised accordingly. We then conducted an Internet sur-
vey of 736 dementia caregivers comparing QDRS to other
validated dementia scales including Revised Memory-
Behavior Problem Checklist (RMBP) [12], patient- and
caregiver-reported Quality of Life (QoL) [13], and the Zarit
Burden Inventory (ZBI) [14]. QDRS scores increased with
dementia severity corresponding with increases in reporting
of increasing memory and behavior problems by RMBP,
increased caregiver burden by ZBI, and decreases in patient-
and caregiver-reported QoL (all Ps , .001). Principlecomponent analysis using Varimax rotation of the QDRS
from this sample revealed two domains: Cognitive (Eigen-
value 4.8; 48.4% variance) and Behavioral (Eigenvalue
1.6; 15.9% variance). This final version of the QDRS was
used in this study.
2.2. Study participants
Participants were drawn from a consecutive series of 239
new patient referrals from September 2013 to November
2014. An additional cohort of 28 healthy controls and their
informants was recruited from the community during this
same time period and underwent identical assessments as
the cases. Assessments were completed by a transdisci-
plinary team of a neurologist, geriatric nurse practitioner, so-
cial worker, and psychometrician. The QDRS was
completed by the caregiver before the visit. During the visit,
the patient and caregiver underwent a comprehensive evalu-
ation including the CDR-SB [11], mood, neuropsychologi-
cal testing, caregiver ratings of behavior and function, and
caregiver burden and depression. All components of the
assessment were part of standard of care at our center [15].
The study was approved by the NYU Langone Medical Cen-
ter Institutional Review Board.
2.3. Administration of the QDRS
Before the office visit, a welcome packet was mailed to
the patient and caregiver to collect demographics. The care-
giver was asked to complete the QDRS and bring it with
them to the office visit. The study team was blinded to the
QDRS, and it was not considered during the clinical assess-
ment, diagnosis, or staging. The QDRS total score is derived
by summing up the 10 domains. Two subdomains cognitive
(questions 1, 2, 3, and 8) and behavioral (questions 4, 5, 6, 7,
9, and 10) were derived from the formative work. The first
six domains of the QDRS were used to generate a QDRS-
derived global CDR and CDR-SB using the published
CDR scoring rules [11].
2.4. Clinical assessment
The neurologist conducted independent semistructured
interviews with the patient and a collateral source. The
CDR [11] was used to determine the presence or absence
of dementia and to stage its severity. The CDR rates cogni-
tive function in six categories (memory, orientation, judg-
ment and problem solving, and performance in community
affairs, home and hobbies, and personal care); a global
CDR 0 indicates no dementia; CDR 0.5 represents MCI or
very mild dementia; CDR 1, 2, or 3 corresponds to mild,
moderate, or severe dementia. Diagnoses were determined
using standard criteria for MCI due to AD [1], MCI possibly
due to other disorders [2], AD [3], dementia with Lewy
Bodies (DLB) [16], frontotemporal degeneration (FTD)
[17,18], and vascular dementia (VaD) [19]. In addition to
the CDR, the Global Deterioration Scale (GDS) [20] was
Table 1
The QDRS, Quick Dementia Rating System
1. Memory and recall
0 No obvious memory loss or inconsistent forgetfulness that does not interfere with function in everyday activities
0.5 Consistent mild forgetfulness or partial recollection of events that may interfere with performing everyday activities; repeats questions/statements,
misplaces items, forgets appointments
1 Mild to moderate memory loss; more noticeable for recent events; interferes with performing everyday activities
2 Moderate to severe memory loss; only highly learned information remembered; new information rapidly forgotten
3 Severe memory loss, almost impossible to recall new information; long-term memory may be affected
2. Orientation
0 Fully oriented to person, place, and time nearly all the time
0.5 Slight difficulty in keeping track of time; may forget day or date more frequently than in the past
1 Mild to moderate difficulty in keeping track of time and sequence of events; forgets month or year; oriented to familiar places but gets confused
outside familiar areas; gets lost or wanders
2 Moderate to severe difficulty, usually disoriented to time and place (familiar and unfamiliar); frequently dwells in past
3 Only oriented to their name, although may recognize family members
3. Decision making and problem-solving abilities
0 Solves everyday problems without difficulty; handles personal business and financial matters well; decision-making abilities consistent with past
performance
0.5 Slight impairment or takes longer to solve problems; trouble with abstract concepts; decisions still sound
1 Moderate difficulty with handling problems and making decisions; defers many decisions to others; social judgment and behavior may be slightly
impaired; loss of insight
2 Severely impaired in handling problems, making only simple personal decisions; social judgment and behavior often impaired; lacks insight
3 Unable to make decisions or solve problems; others make nearly all decisions for patient
4. Activities outside the home
0 Independent in function at the usual level of performance in profession, shopping, community and religious activities, volunteering, or social groups
0.5 Slight impairment in these activities compared with previous performance; slight change in driving skills; still able to handle emergency situations
1 Unable to function independently but still may attend and be engaged; appears “normal” to others; notable changes in driving skills; concern about
ability to handle emergency situations
2 No pretense of independent function outside the home; appears well enough to be taken to activities outside the family home but generally needs to be
accompanied
3 No independent function or activities; appear too ill to be taken to activities outside the home
5. Function at home and hobby activities
0 Chores at home, hobbies and personal interests are well maintained compared with past performance
0.5 Slight impairment or less interest in these activities; trouble operating appliances (particularly new purchases)
1 Mild but definite impairment in home and hobby function; more difficult chores or tasks abandoned; more complicated hobbies and interests
given up
2 Only simple chores preserved, very restricted interest in hobbies which are poorly maintained
3 No meaningful function in household chores or with prior hobbies
6. Toileting and personal hygeine
0 Fully capable of self-care (dressing, grooming, washing, bathing, toileting)
0.5 Slight changes in abilities and attention to these activities
1 Needs prompting to complete these activities but may still complete independently
2 Requires some assistance in dressing, hygiene, keeping of personal items; occasionally incontinent
3 Requires significant help with personal care and hygiene; frequent incontinence
7. Behavior and personality changes
0 Socially appropriate behavior in public and private; no changes in personality
0.5 Questionable or very mild changes in behavior, personality, emotional control, appropriateness of choices
1 Mild changes in behavior or personality
2 Moderate behavior or personality changes, affects interactions with others; may be avoided by friends, neighbors, or distant relatives
3 Severe behavior or personality changes; making interactions with others often unpleasant or avoided
8. Language and communication abilities
0 No language difficulty or occasional word searching; reads and writes as in the past
0.5 Consistent mild word finding difficulties, using descriptive terms or takes longer to get point across, mild problems with comprehension, decreased
conversation; may affect reading and writing
1 Moderate word finding difficulty in speech, cannot name objects, marked reduction in work production; reduced comprehension, conversation,
writing, and/or reading
2 Moderate to severe impairments in speech production or comprehension; has difficulty in communicating thoughts to others; limited ability to read or
write
3 Severe deficits in language and communication; little to no understandable speech is produced
9. Mood
0 No changes in mood, interest, or motivation level
0.5 Occasional sadness, depression, anxiety, nervousness, or loss of interest/motivation
1 Daily mild issues with sadness, depression, anxiety, nervousness, or loss of interest/motivation
2 Moderate issues with sadness, depression, anxiety, nervousness, or loss of interest/motivation
(Continued )
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Table 1
The QDRS, Quick Dementia Rating System (Continued )
3 Severe issues with sadness, depression, anxiety, nervousness, or loss of interest/motivation
10. Attention and concentration
0 Normal attention, concentration, and interaction with his or her environment and surroundings
0.5 Mild problems with attention, concentration, and interaction with environment and surroundings, may appear drowsy during day
1 Moderate problems with attention and concentration, may have staring spells or spend time with eyes closed, increased daytime sleepiness
2 Significant portion of the day is spend sleeping, not paying attention to environment, when having a conversation may say things that are illogical or
not consistent with topic
3 Limited to no ability to pay attention to external environment or surroundings
Cognitive subtotal (questions 1, 2, 3, 8)
Behavioral subtotal (questions 4, 5, 6, 7, 9, 10)
Total QDRS score
NOTE. The following descriptions characterize changes in the patient’s cognitive and functional abilities. You are asked to compare the patient now to how
they used to be—the key feature is change. Choose one answer for each category that best fits the patient—NOTE, not all descriptions need to be present to
choose an answer.
Copyright 2013 The Quick Dementia Rating System James E. Galvin and New York University Langone Medical Center.
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construct of subjective cognitive impairment (SCI). Extrapy-
ramidal features were assessed with the Movement Disor-
ders Society-Unified Parkinson’s Disease Rating Scale,
motor subscale part III [21].
2.5. Caregiver evaluation
Caregivers completed evaluations to determine the pres-
ence and severity of noncognitive symptoms observed in
the patient and their impact on the caregiver. The Neuropsy-
chiatric Inventory (NPI) [22] assessed behavior, Mayo Fluc-
tuation Questionnaire [23] assessed the presence of
cognitive fluctuations, and Epworth Sleepiness scale [24] as-
sessed daytime sleepiness. The Functional Activities Ques-
tionnaire (FAQ) [25] was used to rate the performance of
activities of daily living. The ZBI [14] evaluated caregiver
burden and the Personal Health Questionnaire [26] assessed
caregiver depression.
2.6. Neuropsychological evaluation
Each patient was administered a 30-minute test battery at
the time of the office visit to assess their cognitive status. The
psychometrician was unaware of the diagnosis, QDRS, or
CDR. A brief global assessment was performed using the
Mini-Mental State Examination (MMSE) [27]. The test bat-
tery included measures of episodic memory (Hopkins Verbal
Learning Task [28]; semantic memory (Animal Fluency)
[29] and 15-item Boston Naming Test [30]); and working
memory (Letter-Number Sequencing) [31]. Two timed mea-
sures addressed psychomotor and executive abilities: Trail-
making A [32] and Trailmaking B [32]. Construction was
assessed with the Clock Drawing Task [33]. Mood was as-
sessed with the Hospital Anxiety Depression Scale [34]
providing subscale scores for depression and anxiety.
2.7. Statistical analyses
Analyses were conducted using SPSS v21 (Armonk,
NY). Descriptive statistics were used to present clinicalcharacteristics of patients, informant ratings, QDRS,
CDR, CDR-SB, and neuropsychological testing. One-way
analysis of variance (ANOVA) with Tukey-Kramer post-
hoc tests were used for continuous data and chi-squared an-
alyses were used for categorical data. Eta-squared data
from the omnibus ANOVA were used to estimate effect
size. Data completeness was assessed by calculating the
missing data rates for each QDRS item. To assess item
variability, the item frequency distributions, range, and
standard deviations were calculated. Item and subscale
scores were examined for floor and ceiling effects. Concur-
rent (criterion) validity was assessed comparing the mean
performance on each Gold Standard measure of cognition
(e.g., CDR, CDR-SB, neuropsych testing), function (i.e.,
FAQ), and behavior (e.g., NPI, Hospital Anxiety and
Depression Scale) with the QDRS using Pearson correla-
tion coefficients [9,35,36]. Convergent and discriminative
construct validity was assessed with Spearman correlation
coefficients. For convergent validity, moderate
correlations (r.0.4) between items in each domain and
between similar constructs in rating scales or
neuropsychological tests were accepted as evidence. For
discriminant validity, low correlation (r,0.3) between
items in different domains and between nonsimilar rating
scales and neuropsychological tests was accepted
[9,35,36]. Internal consistency was examined as the
proportion of the variability in the responses that is the
result of differences in the respondents, reported as the
Cronbach alpha reliability coefficient. Coefficients greater
than 0.7 are good measures of internal consistency
[9,35,36]. The intraclass correlation coefficient (ICC)
assessed interscale reliability comparing CDR domains,
SB, and global scores with the QDRS correcting for chance
agreement [9,35,36]. Simple agreement (i.e., the proportion
of responses in which two observations agree such as a
Pearson or Spearman correlation coefficient) is strongly
influenced by the distribution of positive and negative
responses, and the agreement by chance alone. The ICC
instead examines the proportion of responses in
agreement in relation to the agreement expected by
Table 2
Sample characteristics
CDR 0,
controls,
N 5 32
CDR 0,
SCI,
N 5 8
CDR 0.5,
MCI,
N 5 65
CDR 0.5,
dementia,
N 5 60
CDR 1,
dementia,
N 5 60
CDR 2,
dementia,
N 5 31
CDR 3,
dementia,
N 5 11 P-value
Partial
eta
Age, yrs 70.1 (7.6) 70.5 (10.0) 76.2 (8.9) 78.4 (7.1) 77.1 (7.9) 81.6 (7.6) 78.8 (12.3) .05
Education, yrs 16.7 (2.4) 18.1 (1.8) 15.9 (3.0) 15.5 (4.0) 15.4 (3.9) 14.5 (3.0) 14.1 (3.7) .07
Gender, %
female
57.9 50.0 51.5 50.9 50.0 71.0 45.5 .45
Race, % white 93.0 100.0 89.4 93.0 82.3 93.5 100.0 .76
Charlson
Comorbidity
Index
1.7 (1.9) 1.5 (1.8) 1.9 (1.3) 2.3 (1.6) 2.1 (1.1) 2.7 (1.8) 2.5 (1.3) .128
MMSE 26.3 (2.4)* 28.7 (1.6) 26.1 (3.3) 23.4 (2.9) 20.5 (5.1) 14.3 (5.5) 4.3 (5.4) ,.001
GDS 1.0 (0.0) 2.0 (0.0) 3.0 (0.0) 3.9 (0.2) 4.2 (0.5) 5.4 (0.5) 6.2 (0.4) ,.001
FAQ 0.0 (0.0) 2.6 (2.9) 3.6 (4.2) 4.3 (5.1) 12.7 (6.9) 21.8 (7.5) 29.8 (0.4) ,.001
NPI 0.9 (1.6) 4.1 (5.3) 5.6 (4.7) 6.4 (5.3) 9.6 (6.3) 10.7 (5.2) 14.4 (6.1) ,.001
QDRS total 0.3 (0.5) 2.5 (1.7) 3.5 (2.7) 4.1 (2.9) 8.7 (4.1) 13.5 (4.7) 23.7 (3.1) ,.001 0.653
QDRS cognitive 0.2 (0.3) 1.1 (0.6) 1.5 (0.9) 2.1 (1.3) 3.3 (1.7) 4.6 (2.1) 8.5 (1.7) ,.001 0.553
QDRS
behavioral
0.2 (0.3) 1.5 (0.6) 2.0 (2.0) 2.0 (1.9) 5.4 (2.9) 8.8 (3.7) 15.2 (1.7) ,.001 0.628
QDRS sum box 0.2 (0.3) 1.1 (1.1) 1.9 (1.6) 2.4 (1.6) 4.9 (2.2) 8.9 (2.8) 14.9 (1.7) ,.001 0.733
QDRS CDR
global
0.03 (0.1) 0.3 (0.2) 0.4 (0.3) 0.5 (0.3) 0.9 (0.4) 1.6 (0.6) 2.8 (0.4) ,.001 0.678
Abbreviations: CDR, Clinical Dementia Rating; SCI, subjective cognitive impairment; MCI, mild cognitive impairment; MMSE, Mini-Mental State Exam-
ination; GDS, Global Deterioration Scale; FAQ, Functional Activities Questionnaire; NPI, Neuropsychiatric Inventory; QDRS, Quick Dementia Rating System.
*CDR 0 controls completed the Montreal cognitive assessment instead of the MMSE.
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good agreement, whereas an ICC greater than 0.76 is
considered excellent [37]. Receiver operator characteristic
(ROC) curves were used to assess discrimination between
groups using the CDR as a gold standard. Results are re-
ported as area under the curve (AUC) with 95% confidence
intervals (CIs).3. Results
3.1. Sample characteristics
The mean age of the cohort was 77.7 6 8.3 years (range
50–98) with a mean education of 15.56 3.6 years (range 4–
24); a mean Charlson Comorbidity Index [38] of 2.2 6 1.4
(range 0–9); and mean MMSE of 21.8 6 6.3 (range 0–30).
The racial and ethnic make-up of the sample was 89.7%
white, non-Hispanic, 4.3% African American, 4.7% Hispan-
ic, and 1.2% Asian. The cohort diagnoses were 32 healthy
controls, 8 SCI, 65 MCI, 91 AD, 48 DLB, 5 VaD, 10 FTD,
and 8 other dementias. Informants consisted of 156
spouses/significant others, 76 adult children, 13 other rela-
tives, 19 friends, and 3 paid caregivers. Sample characteris-
tics and QDRS scores by diagnosis and stage are presented in
Table 2. QDRS total and subdomain scores increased with
higher CDR staging and poor performance on the MMSE,
FAQ, GDS, and NPI (all Ps, .001). The strength of associ-
ation (concurrent validity) between the QDRS and the CDR
was 0.801 (P , .001) and for the CDR-SB was 0.820
(P, .001). Table 3 demonstrates the strength of association
between the QDRS and other indices of cognition, behavior,and function. The QDRS was not correlated with patient-
reported anxiety (R 5 0.121, P 5 .09) or caregiver depres-
sion (R 5 0.163, P 5 .08).3.2. QDRS data quality
Table 4 demonstrates that all items of the QDRS ex-
hibited the full range of possible responses across the five-
item response options. In general, the item responses were
more heavily distributed between the CDR 0, 0.5, and 1
scores than the CDR 2 and 3 scores (means range from 0.5
to 0.9). Missing item rates were very low ranging from 0%
to 1.7%. The item-level floor effects range from 14.5%
(Memory and Recall) to 56.8% (Toileting and Personal Hy-
giene) with a median of 26.1%. The item-level ceiling ef-
fects range from 0.4% (Orientation) to 8.7% (Mood) with
a median of 3.9%. The standard deviation was similar for
all items, ranging from 0.6 to 0.9. There was no difference
in QDRS scoring between spouse and nonspouse informants
compared with gold standard ratings of cognition, function,
or behavior (F 5 0.032, P 5 .86). Thus, data quality for the
QDRS were excellent.3.3. Reliability and scale score features of QDRS
The degree to which the QDRS was free from random er-
ror by assessing the internal consistency with Cronbach
alpha for Total QDRS scores and two subdomains: cognitive
and behavioral. The internal consistency was excellent
(0.86–0.93, Table 5). The QDRS covered the entire range
of possible scores and the mean, median, and standard
Table 3
Mean performance on rating scales and neuropsychological tests and
concurrent validity with QDRS
Measure Mean (SD) R P-value Covariance
CDR-SB 5.2 (4.4) .820 ,.001 20.4
CDR 0.9 (0.7) .801 ,.001 3.2
GDS 4.0 (1.0) .699 ,.001 4.0
FAQ 9.9 (9.5) .830 ,.001 46.3
UPDRS 12.5 (18.3) .462 ,.001 40.4
MMSE 21.8 (6.4) 2.599 ,.001 221.0
Animal naming 11.3 (6.1) 2.485 ,.001 215.4
BNT 9.3 (4.2) 2.329 ,.001 27.1
HVLT-total 12.4 (5.6) 2.454 ,.001 212.9
HVLT-delay 1.6 (2.4) 2.299 ,.001 23.7
L-N sequence 3.6 (1.4) 2.353 ,.001 22.3
Trailmaking A 68.8 (46.6) .369 ,.001 75.8
Trailmaking B 141.4 (44.2) .275 .002 43.6
HADS-anxiety 5.9 (3.5) .121 .09 2.0
HADS-depression 6.1 (3.8) .239 .001 4.4
AD8-patient version 2.7 (1.9) .207 .004 1.9
NPI 7.9 (5.9) .561 ,.001 19.7
MFQ 1.8 (1.2) .554 ,.001 4.0
Epworth Sleepiness Scale 7.3 (4.8) .363 ,.001 10.3
Alertness rating 7.0 (2.0) 2.511 ,.001 26.1
Caregiver burden 17.1 (10.2) .315 ,.001 18.9
Caregiver depression 2.2 (2.7) .163 .08 2.0
Abbreviations: QDRS, Quick Dementia Rating System; SD, standard de-
viation; CDR, Clinical Dementia Rating; GDS, Global Deterioration Scale;
FAQ, Functional Activities Questionnaire; UPDRS, Unified Parkinson Dis-
ease Rating Scale; MMSE, Mini-Mental State Examination; BNT, Boston
Naming Test; HVLT, Hopkins Verbal Learning Test; L-N, Letter-Number
Sequencing test; HADS, Hospital Anxiety and Depression Scale; NPI,
Neuropsychiatric Inventory; MFQ, Mayo Fluctuations Questionnaire.
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the assessing and monitoring the presence and severity of de-
mentia with low percentage of missing data. There were very
low floor (2.5–8.7%) and ceiling (0.4%) effects, especially
for cognitive domain questions. The two factors (cognitive
and behavioral) were moderately correlated suggesting
they are related but substantially distinct. The total QDRS
was internally consistent with scale score features that
demonstrated ample dispersion of scores for both the
QDRS total score and subscales.
3.4. Construct validity of the QDRS
Construct validity of the QDRS is the correspondence of
how well each domain corresponds to a theorized trait.
Table 6 lists the QDRS domains and the corresponding rating
scales and neuropsychological tests. Demonstration of mod-
erate to strong correlations (40%) between individual
QDRS domains and rating scales and neuropsychological
tests support convergent validity, suggest the QDRS domain
and the corresponding test tap into similar constructs.
Conversely, low correlations (30%) between individual
QDRS domains and rating scales and neuropsychological
tests support divergent validity, suggest there is no relation-
ship between dissimilar constructs. For example, theMemory
andRecall domain is convergentwith tests of episodic and se-mantic memory, but not with mood, behavior, psychomotor,
or executive function. Function within and outside the home
is convergent with extrapyramidal signs, behavior, alertness,
and episodic memory, but not with mood, semantic memory,
or executive function. Toileting and Personal Hygiene is
convergent with behavior, extrapyramidal signs, and alert-
ness, but not with cognitive performance or mood. Attention
and Concentration is convergent with alertness, behavior, and
fluctuations, but not with mood or cognitive performance.3.5. Known-groups validity of the QDRS
The extent towhich theQDRS total and subscales separate
the known groups of cognitive impairment, defined by CDR
staging, is evidence of known group validity (Table 2) [34]
Omnibus p-tests were significant for total QDRS, Cognitive
and Behavioral subdomains, and QDRS-derived CDR and
CDR-SB (all Ps , .001). Pairwise differences using Tukey-
Kramer tests demonstrated that the CDR 0 group was
different from all other groups (all Ps , .001). The two
CDR 0.5 groups (MCI and Dementia) were different from
all other groups (all Ps , .001) but were not different from
each other. The CDR 1, 2, and 3 groups were different from
each other (allPs, .001). The effect size of theQDRS, based
on the eta-squared values, demonstrated that group member-
ship was robustly defined by total QDRS, Cognitive and
Behavioral subdomains, and QDRS-derived CDR and
CDR-SB scores. The characteristics of the QDRS questions,
total QDRS, Cognitive and Behavioral subdomains, and
QDRS-derived CDR and CDR-SB scores by different de-
mentia etiologies is demonstrated in Table 7. The distribution
of the total QDRS, Cognitive and Behavioral subdomains,
and QDRS-derived CDR and CDR-SB scores by MMSE
cut-offs defining controls, MCI, mild, moderate, and severe
dementia is shown in Table 8.3.6. Operating characteristics
The range of QDRS and CDR-SB scores by global CDR
stages is shown in Table 9. Both the QDRS and CDR-SB
demonstrate a range of scores within each global CDR stage
reflecting the range of symptoms reported by the informant,
and in the case of the CDR the performance of the patient. To
aid in interpreting the QDRS scores, we performed ROC
curves for the QDRS to derive cut-off scores that can assist
clinicians and researchers (Table 9). For discriminating
CDR 0 normal controls (with and without subjective com-
plaints) from CDR 0.5 very mild impairment (which includes
MCI and very mild dementia), a cut-off score of 1.5 provides
the best sensitivity and specificity (AUC 0.846; 95%CI 0.76–
0.93, P, .001). Cut-off scores of six discriminates CDR 0.5
very mild impairment from CDR 1 mild dementia; scores of
12.5 discriminate CDR 1 from CDR 2; and scores of 17.5
discriminate CDR 2 from CDR 3. Studies of diagnostic and
screening instruments often report the findings for separating
extreme groups (dementia and normal) because the results
Table 4
Item distributions, missing rates, factor loading, item-total, and interitem correlations
QDRS domain
Item distribution and missing rates
Factor
loading
Item-total
Pearson R
Item Response counts (%)
Mean SD 0 0.5 1 2 3 Miss
Memory and recall (M/R) 0.8 0.6 14.5 41.9 28.2 13.3 1.2 0.8 .846 .703
Orientation (O) 0.6 0.6 24.9 41.5 24.1 9.1 0.4 0.0 .843 .737
Decision making and problem solving (DM) 0.9 0.7 15.4 36.5 31.1 11.2 5.4 0.4 .631 .877
Activities outside the home (AOH) 0.8 0.8 25.3 31.5 21.2 16.6 3.7 1.7 .784 .870
Function at home and hobby activities (FHH) 0.8 0.9 31.1 24.5 22.0 14.1 6.6 1.7 .708 .862
Toileting and personal hygiene (TPH) 0.5 0.8 56.8 18.3 10.0 9.1 5.8 0.0 .794 .860
Behavior and personality changes (B/P) 0.7 0.9 49.0 14.5 15.8 15.4 4.1 1.2 .691 .797
Language and communication (L/C) 0.5 0.6 37.3 34.4 20.3 6.6 0.8 0.4 .652 .672
Mood (M) 0.9 0.9 23.7 38.8 13.3 14.9 8.7 1.2 .857 .758
attention and concentration (A/C) 0.6 0.6 27.0 40.7 21.6 8.3 1.7 0.8 .710 .790
Interitem correlation matrix M/R O DM AOH FHH TPH B/P L/C M A/C
Memory and recall (M/R) 1
Orientation (O) .705 1
Decision making and problem solving (DM) .619 .713 1
Activities outside the home (AOH) .504 .578 .734 1
Function at home and hobby activities (FHH) .549 .599 .721 .755 1
Toileting and personal hygiene (TPH) .502 .565 .715 .805 .749 1
Behavior and personality changes (B/P) .495 .538 .644 .653 .617 .591 1
Language and communication (L/C) .504 .500 .584 .499 .521 .512 .471 1
Mood (M) .388 .365 .587 .615 .576 .643 .608 .346 1
attention and concentration (A/C) .445 .507 .654 .633 .638 .668 .588 .597 .583 1
Abbreviation: QDRS, Quick Dementia Rating System.
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characteristics compared with when the mild cognitive
impairment group is included, as would be the case in usual
practice [36]. For purposes of comparison with studies that
compare normal controls with dementia, we ran ROC curves
for the QDRS and CDR-SB. The AUC for the QDRS was
0.911 (95% CI 0.86–0.96) and for the CDR-SB was 0.996
(95% CI 0.99–1.0) demonstrating comparable ability to
discriminate normal controls from dementia.
3.7. Using the QDRS to generate a valid CDR andCDR-SB
Lastly, we compared the interscale reliability between the
QDRS and the CDR to determine whether the QDRS do-
mains were able to generate an accurate CDR and CDR-
SB (Table 10). The first six QDRS domains were compared
with six CDR boxes with intraclass correlation coefficients
(ICC). The QDRS domains were highly reliable in compar-
ison to the longer CDR for each of the six individual boxes,Table 5
QDRS scale score features: internal-consistency reliability, score distributions, an
Domain Items
Reliability Score features and distribu
Cronbach alpha (95% CI) Range Mean Medi
Cognitive 4 0.861 (0.83–0.89) 0–12 2.8 2.0
Behavioral 6 0.915 (0.89–0.93) 0–18 4.3 3.0
Total 10 0.932 (0.92–0.94) 0–30 7.2 5.2
Abbreviation: QDRS, Quick Dementia Rating System.
NOTE. % Floor is the percentage of caregivers who reported the lowest (best)
highest (worst) possible score.the CDR-SB and CDRGlobal Score with ICCs ranging from
0.71 for QDRS Memory and Recall versus CDR Memory to
0.91 for QDRS Toileting and Personal Hygiene versus CDR
Personal Care. There was excellent reliability using the 5-
minute QDRS to generate a derived CDR global score
(ICC 5 0.90) and CDR-SB (ICC 5 0.92). This supports
that the QDRS could be used for inclusion/exclusion criteria
for clinical trials and for population-based studies to quickly
and accurately stage the presence and severity of dementia.4. Discussion
The QDRS is a brief informant-based dementia staging
system that validly and reliably differentiates individuals
with and without dementia and provides the accurate staging
of individuals without the need for a trained research staff.
The QDRS provides an easy way to assess, stage, and
monitor severity of dementia through the input ofd interscore correlations
tion
% Floor % Ceiling
Interscale correlation, Spearman r
an SD Cognitive Behavioral Total
2.1 3.7 0.4 1
4.1 8.7 0.4 .771 1
5.9 2.5 0.4 .896 .973 1
possible score. % Ceiling is the percentage of caregivers who reported the
Table 6
Construct validity of the QDRS
QDRS domain
Assessment
type Convergent (R . 0.4) Divergent (R , 0.3)
Memory and recall Rating scales CDR, GDS, FAQ UPDRS, HADS-A, HADS-D, NPI, MFQ, ESS, alertness
Neuropsych MMSE, HVLT, BNT L-N sequence, TMT-A, TMT-B, clock
Orientation Rating scales CDR, GDS, FAQ HADS-A, HADS-D, NPI, ESS
Neuropsych MMSE, HVLT, Animals L-N sequence, TMT-A, TMT-B, clock
Decision making and
problem solving
Rating scales CDR, GDS, FAQ, MFQ, Alertness UPDRS, HADS-A, HADS-D
Neuropsych MMSE, HVLT, Animals, TMT-A TMT-B, clock
Activities outside
the home
Rating scales CDR, GDS, FAQ, UPDRS, NPI, MFQ, Alertness HADS-A, HADS-D
Neuropsych MMSE, HVLT, Animals, TMT-A BNT, TMT-B, clock, Mini-Cog
Function at home and
hobby activities
Rating scales CDR, GDS, FAQ, UPDRS, NPI, MFQ, Alertness HADS-A, HADS-D, ESS
Neuropsych MMSE, HVLT, Animals BNT, TMT-B, clock, Mini-Cog
Toileting and personal
hygiene
Rating scales CDR, GDS, FAQ, UPDRS, NPI, MFQ, Alertness HADS-A, HADS-D
Neuropsych MMSE BNT, TMT-B, clock, Mini-Cog
Behavior and personality
changes
Rating scales CDR, GDS, FAQ, NPI, MFQ UPDRS, HADS-A, HADS-D
Neuropsych HVLT, animals, BNT, L-N sequence, TMT-A, TMT-B, clock,
Mini-Cog
Language and
communication
Rating scales CDR, GDS, FAQ, UPDRS HADS-A, HADS-D, NPI, MFQ, ESS, alertness
Neuropsych MMSE TMT-A, TMT-B, Clock, Mini-Cog
Mood Rating scales CDR, GDS, FAQ, HADS-A, NPI, MFQ UPDRS, ESS, HADS-A, HADS-D
Neuropsych MMSE, HVLT, animals, BNT, L-N sequence, TMT-A, TMT-B,
clock, Mini-Cog
Attention and
concentration
Rating scales CDR, GDS, FAQ, NPI, MFQ, ESS, Alertness HADS-A, HADS-D
Neuropsych HVLT, animals, BNT, L-N sequence, TMT-A, TMT-B, clock,
Mini-Cog
Abbreviations: CDR, clinical dementia rating; GDS, global deterioration scale; FAQ, functional activities questionnaire; UPDRS, unified Parkinson’s disease
rating scale; HADS-A, Hospital anxiety depression scale-anxiety subscale; HADS-D, hospital anxiety depression scale-depression subscale; NPI, neuropsychi-
atric inventory; MFQ, Mayo fluctuations questionnaire; ESS, Epworth sleepiness scale; MMSE, mini mental state exam; HVLT, Hopkins verbal learning task;
BNT, Boston naming test; L-N, letter number; TMT-A, trailmaking A; TMT-B, trailmaking B.
Table 7
Performance of QDRS across different dementia etiologies
AD, N 5 91 DLB, N 5 48 VaD, N 5 5 FTD, N 5 10 Other, N 5 8 P-value
Age 79.8 (7.5) 78.4 (7.7) 77.2 (6.2) 72.7 (8.2) 70.2 (7.5) .001
Education 15.2 (2.9) 14.5 (3.6) 14.8 (3.4) 16.8 (3.3) 16.9 (3.4) .28
Gender 58.7 38.9 100.0 30.0 55.6 .02
CDR 1.0 (0.6) 1.5 (0.9) 1.7 (0.9) 0.8 (0.8) 1.0 (0.8) ,.001
CDR-SB 5.7 (3.3) 8.8 (5.2) 9.3 (6.3) 5.2 (4.7) 5.0 (4.4) ,.001
Charlson comorbidity 2.3 (1.3) 2.4 (1.5) 2.6 (1.1) 2.0 (1.3) 2.3 (2.6) .93
MMSE 19.6 (5.5) 18.2 (7.7) 19.7 (6.0) 23.6 (1.4) 26.1 (2.2) .005
FAQ 10.5 (8.5) 17.1 (10.1) 16.6 (13.9) 8.1 (9.9) 12.1 (9.9) .001
NPI 7.7 (5.7) 11.6 (5.7) 11.4 (5.6) 10.5 (9.1) 6.9 (4.5) .002
QDRS-memory and recall 0.9 (0.6) 1.1 (0.7) 0.6 (0.4) 0.7 (0.8) 0.7 (0.3) .06
QDRS-orientation 0.7 (0.5) 1.1 (0.7)* 0.6 (0.4) 0.3 (0.4)* 0.5 (0.6)* ,.001
QDRS-decision making and problem solving 0.9 (0.7) 1.4 (0.8)* 0.9 (1.2) 0.9 (0.8) 0.9 (0.8) .002
QDRS-activities outside the home 0.8 (0.6) 1.4 (0.8)* 1.8 (1.3)* 0.7 (0.7) 0.9 (0.8) ,.001
QDRS-function at home and hobby activities 0.8 (0.7) 1.4 (0.9)* 2.0 (1.4)* 0.9 (0.9) 0.8 (0.6) ,.001
QDRS-toileting and personal hygiene 0.5 (0.7) 1.1 (1.1)* 1.9 (1.5)* 0.3 (0.7)* 0.9 (1.1) ,.001
QDRS-behavior and personality changes 0.7 (0.8) 1.2 (1.0)* 0.9 (1.0) 1.0 (0.9) 0.5 (0.9) .02
QDRS-language and communication 0.5 (0.5) 0.9 (0.7)* 0.7 (1.3) 0.6 (0.6) 0.5 (0.2) .02
QDRS-mood 0.8 (0.8) 1.4 (1.1)* 1.3 (1.1) 1.2 (0.8) 1.2 (0.8) .005
QDRS-attention and concentration 0.6 (0.5) 1.0 (0.7)* 1.1 (1.3) 0.7 (0.5) 0.7 (0.6) .001
QDRS total 7.2 (5.1) 11.7 (6.9)* 11.6 (7.8) 7.4 (6.3) 7.4 (5.8) ,.001
QDRS cognitive 3.1 (1.9) 4.5 (2.6)* 2.8 (2.3) 2.7 (2.4) 2.5 (1.9) .005
QDRS behavioral 4.2 (3.5) 7.5 (4.9)* 8.8 (5.9) 5.4 (4.8) 4.4 (4.3) ,.001
QDRS sum box 4.4 (3.1) 7.5 (4.5)* 7.7 (5.0) 3.9 (3.8) 4.5 (4.0) ,.001
QDRS CDR global 0.8 (0.5) 1.4 (0.8)* 1.7 (1.1)* 0.7 (0.5) 0.8 (0.9) ,.001
Abbreviations: QDRS, Quick Dementia Rating System; AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; VaD, Vascular dementia; FTD, fron-
totemporal degeneration; CDR, Clinical Dementia Rating; CDR-SB, Clinical Dementia Rating; SB, sum-of-boxes; MMSE, Mini-Mental State Examination;
FAQ, Functional Activities Questionnaire; NPI, Neuropsychiatric Inventory.
*Post-hoc differences ,0.05.
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Table 8
Performance of QDRS by MMSE classification
MMSE (28–30) MMSE (24–27) MMSE (18–23) MMSE (10–17) MMSE (0–9) P-value
QDRS total 3.9 (2.9) 4.5 (3.2) 8.7 (5.6) 8.4 (5.4) 17.1 (7.3) ,.001
QDRS cognitive 1.6 (1.0) 1.9 (1.1) 3.2 (1.8) 3.5 (2.2) 6.4 (2.9) ,.001
QDRS behavioral 2.4 (2.1) 2.6 (2.6) 5.4 (4.2) 5.0 (3.6) 10.7 (4.8) ,.001
QDRS-derived CDR sum box 2.1 (1.7) 2.5 (1.8) 5.1 (3.2) 5.8 (3.9) 10.8 (4.3) ,.001
QDRS-derived CDR global 0.5 (0.3) 0.5 (0.3) 0.9 (0.6) 1.0 (0.7) 1.9 (0.8) ,.001
Abbreviations: MMSE, Mini-Mental State Examination; QDRS, Quick Dementia Rating System; CDR, Clinical Dementia Rating.
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(3–5 minutes) and simple format for use in clinical practice,
clinical research, and epidemiological projects. Most pa-
tients never receive an evaluation by a neurologist, geriatric
psychiatrist, or geriatrician skilled in dementia diagnoses
and staging. The QDRS has the potential to provide a clearer,
more accurate staging for those patients who are unable to
receive these more specialized services.
The QDRS exhibits excellent data quality including item
and scale score variability with ample dispersion of scores
and low missing data supporting that caregivers were able
to complete the QDRS without assistance. The QDRS
demonstrated excellent known-group validity defined by
our “Gold Standard” CDR and performance of global rating
scales of cognition (i.e., MMSE [27]), behavior (i.e., NPI
[22]), and function (i.e., FAQ [25]). The QDRS discrimi-
nated healthy controls from all other groups and each
impaired group from another. Based on post-hoc tests, the
cognitive and behavioral subdomains equally discriminated
group membership. The QDRS demonstrated excellent in-
ternal consistency, construct, concurrent, and criterion valid-
ity with cognitive domains corresponding closely with
related cognitive tasks and behavioral domains correspond-
ing closely with global ratings. The correspondence of the
QDRS to validated measures of dementia severity, behavior,
and caregiver concerns shows similar strong correlations
regardless of whether the QDRS was completed by paper
or via the Internet, however, no direct testing of paper and
internet versions was performed.Table 9
Discrimination ability of the QDRS by clinical dementia rating stages
CDR QDRS total Range CDR-SB Range
0 1.0 (1.3) 0–4 0.1 (0.2) 0–0.5
0.5 3.8 (2.8) 0–15 2.4 (1.0) 0.5–6
1 8.7 (4.1) 2–21 5.8 (1.3) 3.5–9
2 13.5 (4.7) 6.5–23 11.5 (1.8) 9–15
3 23.7 (3.1) 17–30 17.4 (0.9) 16–18
Comparison Cut-off Sensitivity Specificity AUC (95% CI)
0 vs. 0.5 1.5 0.84 0.75 0.846 (0.76–0.93)
0.5 vs. 1 6.0 0.84 0.66 0.837 (0.78–0.89)
1 vs. 2 12.5 0.83 0.54 0.800 (0.71–0.89)
2 vs. 3 17.5 0.81 0.90 0.932 (0.86–1.0)
Abbreviations: QDRS, Quick Dementia Rating System; CDR, Clinical
Dementia Rating; AUC, area under the curve; 95% CI, 95% confidence in-
tervals.A number of “Gold Standard” evaluations for staging
dementia exist including the CDR [11] and GDS [20].
Other global informant-based ratings of dementia severity
include the Clinician’s Global Impression of Change
(CGIC) [39] and Clinician’s Interview Based Impression
of Change plus Caregiver Input (CIBIC-Plus) [40].
Although commonly used as outcomes for clinical trials,
the CDR, GDS, CGIC, and CIBIC-Plus all require a
well-trained clinician and ample time to conduct the inter-
view making their use in inclusion/exclusion criteria for
clinical trial screening, intermittent monitoring of research
participants, or use in the community challenging. As
opposed to performance-based assessments such as the
MMSE [27] or Montreal Cognitive Assessment [41],
informant-based assessments use intraindividual measures
of change to characterize whether cognitive decline has
occurred and how that decline interferes with social and
occupational functioning. As such, intraindividual assess-
ments are less subject to age, gender, racial, ethnic, cul-
tural, educational, or socioeconomic biases because each
person serves as their own control [6–8]. A potential
drawback of the QDRS and other informant ratings is the
availability of an observant informant. However, no
difference in QDRS scoring and Gold Standard ratings of
cognition, function, or behavior was detected between
spouse informants who are more likely to be living with
the patient and nonspouse informants who included adult
children, other relatives, friends, and paid caregivers.
The QDRS was developed and validated in the context
of a memory disorders clinic where the prevalence of
MCI and dementia is high. Validation of the QDRS in other
settings where dementia prevalence is lower (e.g., commu-
nity samples, primary care practices) is a reasonable next
step. As this is a cross-sectional study, another next step
is to demonstrate the longitudinal properties of the
QDRS and examine its sensitivity to change, response to
treatments and interventions, and as a prognostic tool
(e.g., hospice certification). Like the CDR, the QDRS
does not provide specific diagnoses or etiologic causes
for cognitive impairment, but rather provides an evidence
of presence of impairment, and if present, the stage of
severity. However, the QDRS domains differentially
change depending on dementia etiology. A strength of
this study is that the comprehensive evaluation occurred
within 2 weeks of the informant completing the QDRS,
and that the investigator was blinded to the results of the
Table 10
Interscale reliability between QDRS and CDR domains
QDRS domain CDR domain ICC (95%CI) P-value
Memory and recall Memory 0.715 (0.63–0.78) ,.001
Orientation Orientation 0.751 (0.67–0.81) ,.001
Decision making and problem solving Judgment and problem solving 0.853 (0.81–0.89) ,.001
Activities outside the home Community affairs 0.899 (0.87–0.92) ,.001
Function at home and hobby activities Home and hobbies 0.830 (0.78–0.87) ,.001
Toileting and personal hygiene Personal care 0.908 (0.88–0.93) ,.001
QDRS derived SB CDR-SB 0.924 (0.90–0.94) ,.001
QDRS derived global score CDR global score 0.902 (0.87–0.93) ,.001
Abbreviations: CDR, Clinical Dementia Rating; CDR-SB, Clinical Dementia Rating; SB, sum-of-boxes; QDRS , Quick Dementia Rating System;
ICC, intraclass correlation coefficient.
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tage of the QDRS is that it is brief enough to be printed
on one piece of paper or viewed in a single screenshot
which should maximize its clinical utility. In establishing
the validity and reliability of the QDRS, we wanted to
test its performance in a “real-world” clinic setting with pa-
tients who are referred from the community rather than in a
research sample. Our clinic sample had an admixture of
gender, education, comorbidities, cognitive, behavioral, af-
fective, and motor symptoms, and diagnoses. A disadvan-
tage was that the cohort was largely Caucasian. We have
not yet examined whether two different raters would score
the QDRS similarly (inter-rater reliability).
The QDRS may serve as an effective clinical research
tool for inclusion/exclusion into clinical trials and as an
intermittent assessment in the home setting improving reten-
tion in research studies. In this study, the QDRS performed
as validly and reliably in staging individuals as the much
longer CDR. Early detection will be important to enable
future interventions at the earliest stages when they are
likely to be most effective. This study provides evidence-
based methodology to use the QDRS to identify and stage in-
dividuals in clinical practice and for participation in clinical
trials, prevention studies, community surveys, and
biomarker research.Acknowledgments
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1. Systematic review: The author reviewed the litera-
ture using traditional (e.g., PubMed) sources. Gold
standard dementia staging scales such as the Clinical
Dementia Rating or Global Deterioration Scale are
commonly used in clinical trials and research pro-
jects but require extensive clinician training and an
extended period of time with the patient and care-
giver. This is impractical for recruitment and eligi-
bility screening for studies or in clinical practice.
2. Interpretation: Our findings support the Quick De-
mentia Rating System (QDRS), may provide a rapid
method to determine eligibility for clinical trials and
research projects; stage patients in clinical practice;
and improve case ascertainment and staging in pop-
ulation studies.
3. Future directions: These results highlight future
studies including the validation of the QDRS in other
settings where dementia prevalence is lower (com-
munity cohort, primary care), and examining the lon-
gitudinal properties of the QDRS and examine its
sensitivity to change, response to interventions, and
as a prognostic tool.
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